DOI:
10.1055/s-00000072
Seminars in Reproductive Medicine
LinksClose Window
References
Chia SK, Ellard SL, Mates M. , et al.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res 2017;
19 (01) 54
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.